Assessment of intraretinal hyperreflective foci using multimodal imaging in eyes with age-related macular degeneration.
AMD
CFP
Intraretinal hyperreflective foci
OCT
age-related macular degeneration
colour fundus photography
Journal
Acta ophthalmologica
ISSN: 1755-3768
Titre abrégé: Acta Ophthalmol
Pays: England
ID NLM: 101468102
Informations de publication
Date de publication:
18 May 2023
18 May 2023
Historique:
revised:
03
05
2023
received:
17
03
2023
accepted:
05
05
2023
pmc-release:
18
11
2024
medline:
18
5
2023
pubmed:
18
5
2023
entrez:
18
5
2023
Statut:
aheadofprint
Résumé
This study aimed to investigate the correspondence between intraretinal hyperreflective foci (IHRF) identified on optical coherence tomography (OCT) B-scans with hyperpigmentation on colour fundus photography (CFP) or hyperreflectivity on infrared reflectance (IR) images in eyes with age-related macular degeneration (AMD). Flash CFP, IR images and OCT B-scans obtained at the same visit were evaluated. Individual IHRF identified on OCT B-scans were assessed for the qualitative presence or absence of a hypotransmission tail into the choroid. The corresponding IR image obtained at the time of OCT acquisition was analysed for the presence or absence of hyperreflectivity in this region. The IR images were manually registered to the CFP image, and CFP images were inspected for the presence or absence of hyperpigmentation at the location of IHRF. From 122 eyes, a total of 494 IHRF were evaluated. For the primary analysis of qualitative presence or absence of hyperpigmentation on CFP and hyperreflectivity on IR at the locations corresponding to IHRF on OCT, 301 (61.0%) of the IHRFs demonstrated evidence of hyperpigmentation on CFP, while only 115 (23.3%) showed evidence of hyperreflectivity on IR. The qualitative determination of the presence or absence of an abnormality on CFP or IR were significantly different (p < 0.0001). 327 (66.2%) of the IHRF showed hypotransmission, and 80.4% of these IHRF showed hyperpigmentation on CFP, though only 23.9% (p < 0.0001) demonstrated hyperreflectivity on IR. Less than two-thirds of IHRF evident on OCT manifest as hyperpigmentation on colour photos, though IHRF with posterior shadowing are more likely to be evident as pigment. IR imaging appears to be even more poorly sensitive for visualizing IHRF.
Identifiants
pubmed: 37199278
doi: 10.1111/aos.15708
pmc: PMC10656356
mid: NIHMS1911841
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NEI NIH HHS
ID : R01 EY023164
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY030614
Pays : United States
Organisme : NEI NIH HHS
ID : RO1EY023164
Pays : United States
Organisme : NEI NIH HHS
ID : R01EY030614
Pays : United States
Informations de copyright
© 2023 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.
Références
Arch Ophthalmol. 2005 Nov;123(11):1570-4
pubmed: 16286620
Ophthalmol Sci. 2022 Jan 24;2(2):100116
pubmed: 36249700
Arch Ophthalmol. 2004 Apr;122(4):477-85
pubmed: 15078664
Ophthalmology. 2013 Dec;120(12):2656-2665
pubmed: 23830761
Retina. 2022 Feb 1;42(2):388-395
pubmed: 34510128
Lancet Glob Health. 2014 Feb;2(2):e106-16
pubmed: 25104651
Ophthalmology. 2013 May;120(5):1038-45
pubmed: 23352193
Ophthalmology. 2002 Oct;109(10):1767-79
pubmed: 12359593
Invest Ophthalmol Vis Sci. 2018 Jul 2;59(8):3431-3439
pubmed: 30025092
Ophthalmology. 2017 Dec;124(12):1764-1777
pubmed: 28847641
Front Immunol. 2021 Apr 22;12:613051
pubmed: 33968016
Ophthalmology. 2013 Apr;120(4):844-51
pubmed: 23332590
Ophthalmology. 2009 Mar;116(3):488-496.e2
pubmed: 19167082
Arch Ophthalmol. 2003 Nov;121(11):1621-4
pubmed: 14609922
Ophthalmol Sci. 2022 Jun;2(2):
pubmed: 35935092
Invest Ophthalmol Vis Sci. 2006 Jul;47(7):3098-108
pubmed: 16799056
Arch Ophthalmol. 2005 Nov;123(11):1484-98
pubmed: 16286610
Retina. 2015 May;35(5):859-65
pubmed: 25768253
Invest Ophthalmol Vis Sci. 2021 Aug 2;62(10):34
pubmed: 34448806
Ophthalmology. 2020 Jan;127(1):P1-P65
pubmed: 31757502
Am J Ophthalmol. 2001 Nov;132(5):668-81
pubmed: 11704028
Invest Ophthalmol Vis Sci. 2017 Sep 1;58(11):4769-4777
pubmed: 28973322
Can J Ophthalmol. 2021 Oct;56(5):325-334
pubmed: 33539821
Ophthalmology. 1999 Sep;106(9):1830-40
pubmed: 10485559
Arch Ophthalmol. 2004 Apr;122(4):564-72
pubmed: 15078675
Ophthalmol Retina. 2020 Nov;4(11):1059-1068
pubmed: 32389889
Retina. 2015 Apr;35(4):638-47
pubmed: 25650713
Ophthalmology. 2011 Apr;118(4):687-93
pubmed: 21093923
Curr Eye Res. 2022 Sep;47(9):1294-1299
pubmed: 35603911
Ophthalmic Physiol Opt. 2016 May;36(3):303-16
pubmed: 27112225
Invest Ophthalmol Vis Sci. 2017 May 1;58(6):BIO211-BIO226
pubmed: 28785769
Retina. 2019 Aug;39(8):1540-1550
pubmed: 29746403
Graefes Arch Clin Exp Ophthalmol. 2019 Jan;257(1):41-48
pubmed: 30374616
Diabetes. 2022 Dec 1;71(12):2685-2701
pubmed: 36203331
Quant Imaging Med Surg. 2022 May;12(5):2932-2946
pubmed: 35502369
Graefes Arch Clin Exp Ophthalmol. 2017 Aug;255(8):1551-1558
pubmed: 28534244